Phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
| Autor: | Linong Ji, Jianhua Ma, Weiping Lu, Jingdong Liu, Jiao’e Zeng, Jialin Yang, Wei Li, Xiuzhen Zhang, Xinhua Xiao, Gen Takayanagi, Yi Wang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Journal of Diabetes Investigation, Vol 12, Iss 4, Pp 537-545 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2040-1124 2040-1116 |
| DOI: | 10.1111/jdi.13389 |
| Popis: | Abstract Aims/Introduction Although the efficacy of teneligliptin, a highly selective dipeptidyl peptidase‐4 inhibitor, has been amply studied for the treatment of type 2 diabetes, no clinical trials of teneligliptin have been carried out in China. We evaluated the efficacy and safety of teneligliptin monotherapy compared with a placebo in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Materials and Methods This multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study, carried out at 42 sites, enrolled type 2 diabetes patients with glycosylated hemoglobin 7.0 to |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|